Nexalin Technology

Nexalin Technology is a Houston-based medical device company designing and developing non-invasive neurostimulation products for mental health conditions. Its cranial electrotherapy stimulation (CES) headset devices — Generation 1 through Generation 3 — are designed to treat anxiety, insomnia, depression, substance use disorder, traumatic brain injury, post-traumatic stress disorder, opioid addiction, alcoholism, chronic pain, and Alzheimer's disease/dementia without drugs or psychotherapy. The company listed on Nasdaq in September 2022; on August 27, 2026 its board approved a 1-for-30 reverse stock split to maintain compliance with the Nasdaq bid-price rule, with split-adjusted trading expected to begin August 31, 2026.